Charles River amps up its biologics testing

Charles River Laboratories ($CRL) is kicking off an all-encompassing service that will allow its biotech and pharma clients to hand over their quality-control testing for biologics en masse, a method the preclinical CRO says can save time and money. Under a platform dubbed RightSource, Charles River and its clients will first determine the ideal split between in- and outsourcing, and then the CRO will take over, managing QC testing through its own labs, its sponsors' facilities and some external vendors. That flexible yet centralized approach will make for speedy, cost-effective biologics and biosimilars testing, according to Charles River. More

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.